ADC Therapeutics Q2 Adj EPS $(0.37) Beats $(0.44) Estimate, Sales $19.28M Miss $34.77M Estimate
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics (NYSE:ADCT) reported Q2 adjusted losses of $(0.37) per share, beating the analyst consensus estimate of $(0.44) by 15.91%. However, the company's quarterly sales of $19.28 million missed the analyst consensus estimate of $34.77 million by 44.55%.
August 08, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ADC Therapeutics' Q2 earnings beat estimates but sales fell short, which could lead to mixed market reactions.
ADC Therapeutics' Q2 earnings beat estimates, which is positive for the stock. However, the company's sales missed estimates, which is negative. These two factors could offset each other, leading to a neutral impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100